Di Yi Cai Jing·2026-01-15 00:20Group 1 - The core viewpoint of the article is that the Hong Kong innovative drug sector has seen a significant recovery in liquidity since the beginning of 2026, leading to a positive market outlook [1] - The report highlights that the upcoming JPM Healthcare Conference is expected to further boost the Chinese biopharmaceutical (BD) transactions, which have already shown substantial growth compared to the same period last year [1] - Huatai Securities anticipates that the liquidity recovery at the start of the year will trigger a clear beta rally in innovative drugs, with expectations of breaking previous highs [1] Group 2 - The external demand-driven Contract Research Organization (CXO) sector is expected to continue exceeding performance expectations due to the demand for new molecules, potentially resonating with the innovative drug sector [1]